Match!

The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan

Published on Aug 1, 2018in International Journal of Cardiology3.47
· DOI :10.1016/j.ijcard.2018.02.075
Yi-Hsin Chan7
Estimated H-index: 7
(CGU: Chang Gung University),
Yung-Hsin Yeh8
Estimated H-index: 8
(CGU: Chang Gung University)
+ 6 AuthorsChi-Tai Kuo21
Estimated H-index: 21
(CGU: Chang Gung University)
View in Source
Abstract
Abstract Background Whether or not non-vitamin K antagonist oral anticoagulants (NOACs) are associated with a lower risk of acute kidney injury (AKI) in patients with non-valvular atrial fibrillation (NVAF) remains unknown in real world practice. Methods In this nationwide retrospective cohort study, 1507, 3200, 5765 and 4227 NVAF patients with chronic kidney disease (CKD) and 4368, 16,945, 22,301, and 16,908 NVAF patients without CKD taking apixaban, dabigatran, rivaroxaban, and warfarin, respectively, from June 1, 2012 to December 31, 2016 were enrolled from the Taiwan National Health Insurance Program. Propensity-score weighted method was used to balance covariates across study groups. Patients were followed until occurrence of AKI or end date of study. Results Three NOACs were all associated with a significantly lower risk of AKI compared with warfarin for both CKD-free (hazard ratio, [95% confidential interval]; 0.65, [0.60–0.72] for apixaban; 0.68, [0.64–0.74] for dabigatran; 0.73, [0.68–0.79] for rivaroxaban) and CKD cohorts (0.50, [0.45–0.56] for apixaban; 0.54, [0.49–0.59] for dabigatran; 0.53, [0.49–0.58] for rivaroxaban). The annual incidence of AKI for all NOACs and warfarin increased gradually as the increment of CHA2DS2-VASc for both CKD-free and CKD cohorts after propensity score weighting. The reduced risk of AKI for three NOACs persisted in most subgroups in either CKD-free or CKD cohort. Multivariate analysis indicated that all three NOACs were all associated with lower risk of AKI than warfarin in either CKD-free or CKD cohort. Conclusions All three NOACs are associated with a lower risk of AKI than warfarin among Asians with NVAF in real-world practice.
  • References (28)
  • Citations (5)
References28
Newest
#1Xiaoxi YaoH-Index: 13
#2Navdeep Tangri (UM: University of Manitoba)H-Index: 27
Last.Peter A. Noseworthy (Mayo Clinic)H-Index: 32
view all 7 authors...
34 CitationsSource
#1Peter Brønnum Nielsen (AAU: Aalborg University)H-Index: 31
#2Flemming Skjøth (AAU: Aalborg University)H-Index: 26
Last.Torben Bjerregaard Larsen (AAU: Aalborg University)H-Index: 35
view all 6 authors...
119 CitationsSource
#1Sergey V. Brodsky (OSU: Ohio State University)H-Index: 21
#2Lee A. Hebert (OSU: Ohio State University)H-Index: 54
10 CitationsSource
28 CitationsSource
71 CitationsSource
#1Ziad Hijazi (Uppsala University)H-Index: 24
#2Stefan H. Hohnloser (Goethe University Frankfurt)H-Index: 68
Last.Lars Wallentin (Uppsala University)H-Index: 124
view all 12 authors...
55 CitationsSource
#1Torben Bjerregaard Larsen (AAU: Aalborg University)H-Index: 35
#2Flemming Skjøth (AAU: Aalborg University)H-Index: 26
Last.Gregory Y.H. Lip (University of Birmingham)H-Index: 141
view all 5 authors...
182 CitationsSource
#1Kang-Ling WangH-Index: 25
#2Gregory Y.H. Lip (AAU: Aalborg University)H-Index: 141
Last.Chern-En ChiangH-Index: 42
view all 4 authors...
70 CitationsSource
#1Daniel Caldeira (University of Lisbon)H-Index: 18
#2Nilza Gonçalves (IMM: Instituto de Medicina Molecular)H-Index: 9
Last.Joaquim J. Ferreira (University of Lisbon)H-Index: 44
view all 5 authors...
13 CitationsSource
#1Vinay Narasimha Krishna (UAB: University of Alabama at Birmingham)H-Index: 5
#2David G. Warnock (UAB: University of Alabama at Birmingham)H-Index: 67
Last.Dana V. Rizk (UAB: University of Alabama at Birmingham)H-Index: 14
view all 4 authors...
17 CitationsSource
Cited By5
Newest
#1Fatemeh Samiei (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 1
#2Hanieh Sajjadi (Shahid Beheshti University of Medical Sciences and Health Services)
Last.Jalal Pourahmad (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 26
view all 5 authors...
Source
#1Fulvio PomeroH-Index: 16
#2Francesco Dentali (University of Insubria)H-Index: 37
Last.Daniela MastroiacovoH-Index: 5
view all 7 authors...
Source
#1Adrian V. Hernandez (UConn: University of Connecticut)H-Index: 44
#2George Bradley (UConn: University of Connecticut)
Last.Craig I Coleman (UConn: University of Connecticut)H-Index: 49
view all 10 authors...
Source
#1Chi Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 4
#2Zhi-Chun Gu (SJTU: Shanghai Jiao Tong University)H-Index: 4
Last.Jun Pu (SJTU: Shanghai Jiao Tong University)H-Index: 19
view all 8 authors...
Source
#1Avi Sabbag (Mayo Clinic)H-Index: 1
#2Xiaoxi Yao (Mayo Clinic)H-Index: 13
Last.Peter A. Noseworthy (Mayo Clinic)H-Index: 32
view all 4 authors...
3 CitationsSource
View next paperRenal Outcomes in Anticoagulated Patients With Atrial Fibrillation